Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Prostatic Neoplasms 6268Carcinoma, Renal Cell 1913Urinary Bladder Neoplasms 1670Kidney Neoplasms 930Breast Neoplasms 793Neoplasms 788Carcinoma, Transitional Cell 594Carcinoma, Non-Small-Cell Lung 524Neoplasm Metastasis 510Melanoma 485Ovarian Neoplasms 468Colorectal Neoplasms 454Lung Neoplasms 435Pancreatic Neoplasms 325Testicular Neoplasms 290Stomach Neoplasms 274Sarcoma 267Uterine Cervical Neoplasms 264Non-Muscle Invasive Bladder Neoplasms 263Head and Neck Neoplasms 241Colonic Neoplasms 217Esophageal Neoplasms 203Squamous Cell Carcinoma of Head and Neck 202Carcinoma, Hepatocellular 197Wilms Tumor 196Endometrial Neoplasms 189Recurrence 162Neuroblastoma 148Urologic Neoplasms 147Small Cell Lung Carcinoma 146

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Progressive Castration-resistant Prostate Cancer × Genitourinary × Clear all
NCT02025413 2018-12-20

CTC-EMT

Duke University

Phase NA Completed
46 enrolled
BreastGenitourinary

Metastatic Progressive Castration-resistant Prostate Cancer

NCT01091103 2018-10-23

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Pfizer

Phase 2 Completed
60 enrolled 20 charts
Genitourinary

Metastatic Progressive Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡